The novel Coronavirus disease 2019 (COVID-19) is an illness caused due to Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The World Health Organization (WHO) has declared this outbreak a global health emergency and as on April 24, 2020, it has spread to 213 countries, with 25,91,015 confirmed cases and 742,855 cases have been recovered from COVID-19. In this dreadful situation our team has already published an article in the Science of the Total Environment, which elaborates the various aspects of the SARS-CoV-2 infection. In this situation, it is imperative to understand the possible outcome of COVID-19 recovered patients and determine if they have any other detrimental illnesses by longitudinal analysis to safeguard their life in future. It is necessary

No abstract

Background: Analysing antibiotic susceptibility pattern of uropathogens help to overcome the therapeutic difficulties created by the rising anti-microbial resistant bacteria and guides in choosing appropriate antibiotics. Hence, we aimed at evaluating the uropathogens causing urinary tract infections and study their antibiograms.Methods: Midstream urine samples were collected, cultured and appropriate biochemical tests were performed for proper identification of urinary tract pathogens in State Referral Hospital Falkawn, Mizoram, India from 1st January to 30th June 2018.Results: The most common isolated gram-negative uropathogens were Escherichia coli (40.9%), followed by Klebsiella spp. (17.6%), Proteus spp. (10.7%) and Pseudomonas spp. (3.1%). Among gram-positive organisms Enterococcus spp. (20.1%) and Staphylococcus spp. (7.6%) were grown. Urinary tract infections were more prevalent in girls (64.8%) than boys (35.2%). High level of resistance was found to amoxycillin/ampicillin by all the organisms isolated.Conclusions: Almost all the test organisms exhibited multiple antibiotic resistance. The study identified multiple antibiotics resistance by uropathogens which were earlier used as first line of treatment of UTI in children.

No abstract

Background: Viral hepatitis is a serious public health problem affecting billions of people globally. The Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are blood borne pathogens, frequently causing deaths among general and various high risk populations. This study was carried out with the aim to determine the seroprevalence of HBV and HCV in people who inject drugs (PWID) and other risk groups. Methods: A cross-sectional study carried out in the Dept. of Microbiology, RIMS, Imphal from October 2014 to September 2016. 103 high risk individuals, including PWID, spouse of high risk people, unprotected sex with female sex worker (FSW), multiple partners (MP), men having sex with men (MSM) and needle prick injuries were included in this study. Serum samples were tested using Enzyme linked immunosorbent assay (ELISA). Results: Out of 103 cases, 87.4% were males and 12.6% females. PWID comprised of 49.5%. Seroprevalence of HBV was 17.4%, anti HBc IgG 16.5% and anti HBc IgM 0.9%. Seroprevalence of HCV was 41.7%, anti HCV IgG 39.8% and anti HCV IgM 1.9%. The rate of HBV and HCV coinfection was 9.7%. Among the PWID seroprevalence of HBV and HCV was 17.6% and 64.7% respectively. Conclusions: This study determines the current status of acute and chronic infection with HBV and HCV in high risk populations. Anti HBc IgG & IgM and anti HCV IgG and IgM are sensitive epidemiological markers to determine the burden of the disease.